Increasing Demand for Medical Cannabis is set to Grow Globally

Tuesday, September 18, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

FinancialBuzz.com News Commentary

NEW YORK, September 18, 2018 /PRNewswire/ --

According to data provided

by Mordor Intelligence, the global cannabis market was valued at USD 7.7 Billion in the year 2016 and is expected to reach USD 65 Billion by the year 2023, while maintaining a CAGR of 37% during the forecast period. The report also indicates that the
growth rate is attributed to the legalization of cannabis in various countries, as well as to the increasing demand of cannabis products for medical and recreational purposes. North America accounts for more than 95% of the global market, with the U.S. alone making up more than 90% of the North American, as well as global market. Maricann Group Inc. (OTC: MRRCF), Emblem Corp. (OTC: EMMBF), The Supreme Cannabis Company, Inc. (OTC: SPRWF), Lexaria Bioscience Corp. (OTC: LXRP), India Globalization Capital, Inc. (NYSE: IGC)

Canada's new laws, officially making cannabis products legal from earlier this June, are expected to create a pioneering business environment. A report by CBC, University of Waterloo entrepreneurship professor, Nada Basir, explained, "Where I think we're going to see a lot of startup activity around this new legislation is in activities outside the traditional growth and transaction of the product… typically, historically, this is where we see innovation really happen because it becomes the survival of the fittest, and to survive you're going to have to figure out how to scale, how you can be more efficient, how you can save costs."

Maricann Group Inc. (OTCQB: MRRCF) is also listed on the Canadian Securities Exchange under the ticker (CSE: MARI). Yesterday, through its wholly-owned subsidiary Maricann Inc., the Company announced, "the launch of Kiwi - a straightforward, modern approach to cannabis and the first from the Company's House of Brands - available to Canadian consumers of legal age on October 17, 2018.

Maricann is launching Kiwi as a brand designed to help Canadians learn and experience the product in a straightforward, simple and "jargon-free" way. Rather than launching with technical strains that might confuse new consumers, Kiwi will debut four variants that are easy to follow, regardless of background or expertise. Available in dried flower formats, Kiwi's simple naming system consists of White Feather (High CBD), Hawke's Bay (Balanced), Nelson's Blue (Mid THC) and Flightless Bird (Mid-High THC), which are playful takes on Kiwi's New Zealand-inspired name. Each strain will deliver reliable, consistent sensations that are easy to enjoy."  

'We're in the middle of a rapidly growing industry; one that has sparked a lot of curiosity among consumers. We've built Kiwi to streamline the information and clutter of products - so that cannabis is accessible to a wider public and Canadians can make smart, informed decisions on where we fit in their wellness routine and lifestyle,' said Geoff Kosar, Vice President of Sales & Marketing. 'At its core, Kiwi is a celebration of the simple pleasures, and that starts with simple, straightforward communications.'

Working as Kiwi's Master Grower, industry veteran Jennifer Ayotte brings her exacting standards and dedication to delivering quality cannabis to Maricann's state-of-the-art facilities in Langton, Ontario. 'Cannabis can be simple, elegant and easy-to-understand,' said Jennifer Ayotte, Kiwi Master Grower. 'When the right measures are set in place for consistency, quality and safety, it's easier to see that what we're really talking about are plants.'

Visit kiwicannabis.ca for more information on how to simplify your self-care.

About Maricann Group Inc: Maricann is a vertically integrated producer and distributor of cannabis for medical purposes. The Company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada. The Company also has production operations in Dresden, Saxony, Germany and Regensdorf, Switzerland. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) and will continue to pursue new opportunities in Europe."

Emblem Corp. (OTCQX: EMMBF) is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR. The Company and Natura Naturals Holdings Inc. announced the termination of their letter of intent as of 5 p.m. EST on September 13th, 2018. In addition, as previously announced, Emblem recently provided USD 2 Million of advanced funding to Natura for the expansion of its facility. The Funding is comprised of a one-year convertible debenture for an aggregate principal amount of up to USD 2 Million, with an interest rate similar to Natura's other funding obligations and can be pre-paid at any time during the term. "Emblem looks forward to maintaining its strong business relationship with the Natura team as both a shareholder and in connection with our existing 3,000 kg supply agreement in the coming years," said Nick Dean, CEO of Emblem Corp.

The Supreme Cannabis Company, Inc. (OTCQX: SPRWF) is a Canadian publicly traded company committed to providing premium brands and products that proudly reflect its consumers, people and uniquely innovative culture. The Company's portfolio includes its wholly-owned subsidiary and flagship brand 7ACRES. The Supreme Cannabis Company recently announced that the Company's wholly-owned subsidiary, 7ACRES, has entered into a supply agreement to provide dried cannabis to Tilray Canada Ltd., a subsidiary of Tilray Inc., a global leader in cannabis research, cultivation, processing and distribution currently serving tens of thousands of patients in 11 countries spanning 5 continents. The value of this initial supply agreement is estimated to be in excess of CAD 2 Million.  Dried cannabis provided to Tilray by 7ACRES will be used primarily to support medical cannabis patients in Canada, including Tilray's robust patient population.

Lexaria Bioscience Corp. (OTCQX: LXRP) has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. The Company recently announced strategic additions to its patent portfolio. Three new Australian patents were granted to Lexaria by the Australian Patent Office, bringing the Company's worldwide patent portfolio to eight issued patents: four each in the US and Australia. All eight patents are within Lexaria's first patent family, "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof", and significantly strengthen Lexaria's intellectual property claims in the US and Australia. The Company is concurrently pursuing accelerated examination in Australia based on these US Notices of Allowance and expects two new Australian patents to also be issued prior to year-end 2018. If issued in both the US and Australia, the Company will then hold twelve issued patents within its first patent family and continues to pursue claims in corresponding pending applications within this first patent family around the world.

India Globalization Capital, Inc. (NYSE: IGC) has two lines of business, a legacy infrastructure business and a cannabis pharmaceutical business that has developed a lead product for treating Alzheimer's patients. The Company recently announced that it has raised USD 1.0 Million in a private placement of restricted shares. The net proceeds from the offering are for marketing and working capital associated with the commercialization of Hyalolextm. 869,565 shares of newly issued unregistered common stock were sold at USD 1.15 per share. After fees and expenses, the net proceeds to IGC are approximately USD 1.0 Million. The net proceeds from the offering are for marketing and working capital associated with the commercialization of Hyalolextm. The sale is subject to customary closing conditions, including approval by the NYSE. "We are pleased to receive an investment from a strategic investor who shares IGC's vision and confidence in commercializing our flagship product, Hyalolextm, and our ability to drive long-term shareholder value," said Ram Mukunda, CEO of IGC.

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned within this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For Maricann Group Inc. financial news dissemination and PR services, FinancialBuzz.com has been compensated four thousand dollars by winning media. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com .

For further information: info@financialbuzz.com +1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store